Oxford BioMedica Plc said that its gene therapy for Parkinson’s disease, ProSavin, met is primary endpoint in a Phase 1/2 study which evaluated the safety of the medicine in three ascending doses. Fifteen patients participated in the trial. ---Subscribe to MedNous to access this article--- Company News Research & University News
